摘要
目的应用表面增强激光解析电离飞行时间质谱（SELDI—TOF—MS）检测前列腺癌患者的血清蛋白质指纹图谱，筛选特异性诊断标志物。方法以病理确诊的45例前列腺癌患者血清和45例BPH患者血清为研究对象。采用SELDI蛋白质芯片技术检测血清的蛋白表达图谱，用BiomarkerWizard软件分析差异蛋白，对所得蛋白进行初步诊断分析。结果应用IMAC—CU固相金属亲和芯片在未经治疗的前列腺癌和BPH患者血清中检测到9个差异蛋白质峰，其蛋白质含量差异有统计学意义（P〈0．01），其中7个差异蛋白（3771．14，3968．26，4050．39，4279．20，4464．03，4481．59，8919．34）在前列腺癌患者血清中呈高表达，2个差异蛋白（5440．68，6102．82）呈低表达。联合相对分子质量为3771．14和4481．59的2个差异蛋白诊断前列腺癌，其敏感性为86．7％（39／45），特异性为88．9％（40／45）。经蛋白质数据库搜索，找到6种与差异蛋白相对分子质量最接近的蛋白质，分别为Pepeide YY、Apolipoprotin C-Ⅱ、Glucagon like peptide（7-37）、uncharacterized protein C14orf128、Medin、Neuropeptide Y。结论SELDI蛋白质芯片技术可筛选出前列腺癌中相对特异的潜在标志蛋白，具有较好的临床应用前景。
Objective To detect serum biomarkers in prostate cancer（PCa） patients and benign prostatic hyperplasia （BPH） patients by surface enhanced laser desorption/ionization-time of flight （SELDI-TOF） mass spectrometry. Methods Forty-five PCa patients and forty-five BPH patients serums were screened by SELDI-TOF mass spectrometry. The data of spectra were analyzed by bioinformatics tools, Biomarker Wizard. Results Compared with the spectra of BPH patients, there were 9 potential PCa markers detected in the spectra of the PCa patients. In PCa patients, the protein 3771.14,3968.26,4050.39,4279.20,4464.03,4481.59,8919.34 expression levels were higher and the protein 5440.68,6102. 82 expression levels were lower than in BPH patients. Using 2 biomarkers （3771.14 and 4481.59） to detect PCa resulted in a sensitivity of 86.7% （39/45） and specificity of 88.9% （40/45）. After searching protein database, there were 6 proteins might be potential PCa bio markers, including Peptide YY, Apolipoprotin C Ⅱ, Glucagon like peptide（7-37）, uncharacterized protein C14orf128, Medin and Neuropeptide Y. Conclusion SELDI-TOF mass spectrometry has great potentiality for exploring PCa tumor biomarkers for early diagnosis and screening.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2009年第11期776-779,共4页
Chinese Journal of Urology
关键词
前列腺肿瘤
癌
蛋白质阵列分析
肿瘤标记
生物学
Prostatic neoplasms
Carcinoma
Protein array analysis
Tumor markers, biological
